Thirteen patients received omalizumab for severe asthma at a dose of 150–650 mg, depending on the weight and basal IgE level; five of them had CRSwNP and one of them also had AD. The gene discussed is IGHE; the disease is chronic rhinosinusitis with nasal polyps.